Cendakimab
Cendakimab (RPC4046; ABT 308; CC-93538) is a selective, humanized, recombinant monoclonal antibody against the IL-13 molecule. Cendakimab has a high affinity and potency for both human wild-type and variant IL-13 and blocks binding of IL-13 to both IL-13Rα1 and IL-13Rα2 with IC50s of 352 pM and 631 pM by ELISA, respectively. Cendakimab recognizes both wild-type human IL-13 and the common polymorphic variant R110Q, with binding affinities of 52 and 50 pM, respectively. Cendakimab has the potential for IL-13-related allergic/inflammatory diseases (e.g., asthma and eosinophilic esophagitis) [1].
Product Specifications
CAS Number
2151032-62-9
Product Name Alternative
RPC 4046; ABT 308; CC-93538
UNSPSC
12352203
Target
Interleukin Related
Type
Inhibitory Antibodies
Related Pathways
Immunology/Inflammation
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/cendakimab.html
Purity
99.96
Solubility
H2O
Smiles
[Cendakimab]
Molecular Weight
(146.44 kDa)
References & Citations
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 3
Isoform
IL-13
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
CSK (Tyrosine-protein Kinase CSK, C-SRC Kinase, Protein-tyrosine Kinase CYL) (MaxLight 750) discontinued
Human CEACAM-7 Alexa Fluor 488 MAb (Clone 962720)
